These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 34353064)

  • 1. Evaluation of minor drug-resistant viral variants in patients experiencing virological failure (VF) on a first-line regimen in Fujian Province by high-throughput sequencing.
    Deng Y; Wu S; Qiu L; Yan Y
    Ann Palliat Med; 2021 Jul; 10(7):7775-7785. PubMed ID: 34353064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.
    Lataillade M; Chiarella J; Yang R; DeGrosky M; Uy J; Seekins D; Simen B; St John E; Moreno E; Kozal M
    PLoS One; 2012; 7(2):e30118. PubMed ID: 22355307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failure.
    Vandenhende MA; Bellecave P; Recordon-Pinson P; Reigadas S; Bidet Y; Bruyand M; Bonnet F; Lazaro E; Neau D; Fleury H; Dabis F; Morlat P; Masquelier B
    PLoS One; 2014; 9(1):e86771. PubMed ID: 24475178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV Drug Resistance Mutations (DRMs) Detected by Deep Sequencing in Virologic Failure Subjects on Therapy from Hunan Province, China.
    Chen X; Zou X; He J; Zheng J; Chiarella J; Kozal MJ
    PLoS One; 2016; 11(2):e0149215. PubMed ID: 26895182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use.
    Le T; Chiarella J; Simen BB; Hanczaruk B; Egholm M; Landry ML; Dieckhaus K; Rosen MI; Kozal MJ
    PLoS One; 2009 Jun; 4(6):e6079. PubMed ID: 19562031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen.
    Fisher R; van Zyl GU; Travers SA; Kosakovsky Pond SL; Engelbrech S; Murrell B; Scheffler K; Smith D
    J Virol; 2012 Jun; 86(11):6231-7. PubMed ID: 22457522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological failure and HIV-1 drug resistance mutations among naive and antiretroviral pre-treated patients entering the ESTHER program of Calmette Hospital in Cambodia.
    Barennes H; Guillet S; Limsreng S; Him S; Nouhin J; Hak C; Srun C; Viretto G; Ouk V; Delfraissy JF; Ségéral O
    PLoS One; 2014; 9(8):e105736. PubMed ID: 25166019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.
    Silver N; Paynter M; McAllister G; Atchley M; Sayir C; Short J; Winner D; Alouani DJ; Sharkey FH; Bergefall K; Templeton K; Carrington D; Quiñones-Mateu ME
    AIDS Res Ther; 2018 Nov; 15(1):18. PubMed ID: 30409215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of pretreatment low-abundance HIV-1 drug-resistant variants on virological failure among HIV-1/TB-co-infected individuals.
    Chimukangara B; Giandhari J; Lessells R; Yende-Zuma N; Sartorius B; Samuel R; Khanyile KS; Stray-Pedersen B; Moodley P; Metzner KJ; Padayatchi N; Naidoo K; De Oliveira T
    J Antimicrob Chemother; 2020 Nov; 75(11):3319-3326. PubMed ID: 32772079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
    Simen BB; Simons JF; Hullsiek KH; Novak RM; Macarthur RD; Baxter JD; Huang C; Lubeski C; Turenchalk GS; Braverman MS; Desany B; Rothberg JM; Egholm M; Kozal MJ;
    J Infect Dis; 2009 Mar; 199(5):693-701. PubMed ID: 19210162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of virological failure and HIV drug mutations in a first-line cohort of Malawian children.
    Huibers MHW; Moons P; Cornelissen M; Zorgdrager F; Maseko N; Gushu MB; Iwajomo OH; Boele van Hensbroek M; Calis JCJ
    J Antimicrob Chemother; 2018 Dec; 73(12):3471-3475. PubMed ID: 30169653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep sequencing analysis of M184V/I mutation at the switch and at the time of virological failure of boosted protease inhibitor plus lamivudine or boosted protease inhibitor maintenance strategy (substudy of the ANRS-MOBIDIP trial).
    Delaugerre C; Nere ML; Eymard-Duvernay S; Armero A; Ciaffi L; Koulla-Shiro S; Sawadogo A; Ngom Gueye NF; Ndour CT; Mpoudi Ngolle M; Amara A; Chaix ML; Reynes J;
    J Antimicrob Chemother; 2021 Apr; 76(5):1286-1293. PubMed ID: 33624081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of pretreatment minority HIV-1 reverse transcriptase inhibitor-resistant variants by ultra-deep sequencing has a limited impact on virological outcomes.
    Su B; Zheng X; Liu Y; Liu L; Xin R; Lu H; Huang C; Bai L; Mammano F; Zhang T; Wu H; Sun L; Dai L
    J Antimicrob Chemother; 2019 May; 74(5):1408-1416. PubMed ID: 30668734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru.
    Soria J; Mugruza R; Levine M; León SR; Arévalo J; Ticona E; Beck IA; Frenkel LM
    AIDS Res Hum Retroviruses; 2019 Feb; 35(2):150-154. PubMed ID: 30560685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.
    Kozal MJ; Chiarella J; St John EP; Moreno EA; Simen BB; Arnold TE; Lataillade M
    Antivir Ther; 2011; 16(6):925-9. PubMed ID: 21900725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.
    Castain L; Perrier M; Charpentier C; Palich R; Desire N; Wirden M; Descamps D; Sayon S; Landman R; Valantin MA; Joly V; Peytavin G; Yazdanpanah Y; Katlama C; Calvez V; Marcelin AG; Todesco E
    J Antimicrob Chemother; 2019 Jul; 74(7):2019-2023. PubMed ID: 31050739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 antiretroviral resistance: scientific principles and clinical applications.
    Tang MW; Shafer RW
    Drugs; 2012 Jun; 72(9):e1-25. PubMed ID: 22686620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western India.
    Karade SK; Ghate MV; Chaturbhuj DN; Kadam DB; Shankar S; Gaikwad N; Gurav S; Joshi R; Sane SS; Kulkarni SS; Kurle SN; Paranjape RS; Rewari BB; Gangakhedkar RR
    Medicine (Baltimore); 2016 Sep; 95(37):e4886. PubMed ID: 27631260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.